Protagonist Therapeutics, Inc. (PTGX)

NASDAQ: PTGX · IEX Real-Time Price · USD

34.59

-0.61 (-1.73%)

At close: Jul 2, 2024, 4:00 PM

34.57

-0.02 (-0.06%)

After-hours: Jul 2, 2024, 7:00 PM EDT

Protagonist Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2014
Net Income	-78.96	-127.39	-125.55	-66.15	-77.19	Upgrade
Depreciation & Amortization	3.31	3.37	2.78	2.72	2.52	Upgrade
Share-Based Compensation	29.29	24.2	16.4	7.9	8.35	Upgrade
Other Operating Activities	-23.89	-8.32	-1.48	-16.96	24.78	Upgrade
Operating Cash Flow	-70.24	-108.14	-107.87	-72.48	-41.53	Upgrade
Capital Expenditures	-0.61	-0.8	-1.1	-0.47	-0.97	Upgrade
Change in Investments	-38.65	92.26	-14.76	-90.49	-52.74	Upgrade
Investing Cash Flow	-39.26	91.47	-15.86	-90.97	-53.71	Upgrade
Share Issuance / Repurchase	132.66	14.55	123.83	255.37	34.49	Upgrade
Debt Issued / Paid	0	0	0	-10.52	9.77	Upgrade
Other Financing Activities	37.82	4.29	6.09	2.79	1.78	Upgrade
Financing Cash Flow	170.48	18.84	129.92	247.63	46.04	Upgrade
Exchange Rate Effect	0	-0.09	-0.13	0.18	-0.03	Upgrade
Net Cash Flow	60.98	2.08	6.07	84.35	-49.23	Upgrade
Free Cash Flow	-70.85	-108.93	-108.97	-72.96	-42.49	Upgrade
Free Cash Flow Margin	-118.08%	-409.81%	-398.31%	-254.84%	-18395.67%	Upgrade
Free Cash Flow Per Share	-1.25	-2.22	-2.35	-2.12	-1.64	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).